Abstract 336P
Background
Immune checkpoint inhibitor (ICI) plus Chemotherapy has now become the new standard treatment for non-small-cell lung cancer (NSCLC). However, little is known about comparison of ICI plus Chemotherapy and ICI monotherapy in the real world.
Methods
Patients with PD-L1-positive, advanced NSCLC treated with pembrolizumab plus chemotherapy (C group) or pembrolizumab monotherapy (M group) at Sendai Kousei Hospital between May 2015 to June 2019 were included in our study. C group received different treatments depending on histology: Patients with squamous NSCLC were received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]–paclitaxel plus pembrolizumab followed by pembrolizumab maintenance therapy. Patients with non-squamous NSCLC were received pemetrexed and a platinum-based drug plus pembrolizumab followed by pembrolizumab plus pemetrexed maintenance therapy. Two groups were evaluated with respect to adverse event (AE) profiles, objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS).
Results
The following were observed: patient background (C group/ M group) number of cases 13/ 38 cases, median age 64/ 73 years old, male 76.9/71.1 %, Performance Status 0 or 1/ 2/ ≧3 (13/ 0/ 0) / (36/ 2/ 0), median observation period 5.1/ 7.4 months, development of AEs 100/ 84.2 %, development of immune-rerated AEs (irAEs) 61.5/ 84.2 %, development of irAEs ≥ grade 3 7.7/ 21.1 %. There was no significant difference in the ORR (38.5/ 55.2 %; p = 0.199) and DCR (100/89.5 %; p = 0.561) between two groups. Three months PFS were 100 % in combination group and 76.3 % in monotherapy group. Median PFS wasn’t significant different between the two groups (5.9/ 9.2 months; p = 0.193). PFS within 3 months of treatment start of C group tended to be better than M group.
Conclusions
Median PFS wasn’t significantly different between the two groups, probably due to the short observation period. PFS within 3 months of treatment start of C group tended to be better than M group. C group had more AEs than M group. However, the frequency of severe irAEs in C group was similar to M group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S. Sugawara: Honoraria (self): Ono Pharmaceutical; Honoraria (self): Bristol-Myers Squib; Honoraria (self): MSD; Honoraria (self): AstraZeneca; Honoraria (self): Chugai Pharma; Honoraria (self): Nippon Boehringer Ingelheim; Honoraria (self): Pfizer; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Eli Lilly and Company; Honoraria (self): Novartis; Honoraria (self): Kyowa Hakko Kirin. Y. Toi: Honoraria (self): Ono Pharmaceutical; Honoraria (self): MSD; Honoraria (self): AstraZeneca. Y. Kawashima: Honoraria (self): Chugai Pharma. A. Nakamura: Honoraria (self): MSD; Honoraria (self): Chugai Pharma; Honoraria (self): AstraZeneca. S. Yamanda: Honoraria (self): Kyowa Hakko Kirin; Honoraria (self): Novartis; Honoraria (self): AstraZeneca; Honoraria (self): Taiho Pharmaceutical. Y. Kimura: Honoraria (self): Nippon Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
258P - Assessment of sexual health in patients treated for ovarian cancer
Presenter: Renu Madan
Session: Poster display session
Resources:
Abstract
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract